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Abstract 
Immunological Impact of CLI-095 on Dendritic Cell Maturation and Hypoxia-
re-oxygenation induced inflammatory injury  
Introduction: Ischemia reperfusion injury (IRI) activates innate immunity through 
the engagement of Toll-Like Receptors (TLRs) by endogenous ligands. TLR4 expressed 
within the kidney is a potential mediator of innate activation and inflammation. Stimulation 
of TLR4 induces distinct patterns of gene expression, which not only leads to the activation 
of innate immunity but also to the development of acquired immunity. CLI-095, a novel 
synthetic small-molecule, suppresses production of multiple cytokines by inhibiting TLR4 
signaling. In this study, we have determined the role of TLR4 in hypoxia and re-oxygenation 
injury model, which mimics IRI in vitro, and investigated the effect of CLI-095 (a specific 
TLR4 inhibitor) on TLR4 mediated inflammation and maturation of dendritic cells (DCs). 
Hypothesis:  TLR4 signaling plays an important role in activation of innate 
immunity, and that targeting its pathway with CLI-095 will prevent inflammation and 
subsequent injury caused during hypoxia re-oxygenation. 
Method: Bone marrow derived dendritic cells were stimulated by hypoxia re-
oxygenation with or without CLI-095. Expression of TLR4, proinflammatory cytokines, and 
dendritic cells maturation markers were then tested by Flow Cytometry, qRT-PCR, and 
ELISA. 
Results: We have shown that CLI-095 is able to blocks the TLR4 signaling pathway 
and reduce the expression of pro inflammatory cytokines (IL6 and TNFα) in response to 
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hypoxia re-oxygenation. In addition, DCs that were pretreated with CLI-095 showed low 
expression of maturation markers in comparison to cells that were subjected to hypoxia re-
oxygenation. 
Conclusion: TLR4 is involved in innate immunity activation in response to IRI or 
hypoxia re-oxygenation and CLI-095 is able to block TLR4 signaling pathway and suppress 
the activation of the inflammatory response. Therefore, ameliorating TLR4 by new therapies 
such as CLI-095, which specifically targets TLR4, may have potential implication in 
reducing IRI in clinical transplantation. Since almost all immune cells including DCs express 
TLR4.  
Keywords: 
Kidney, Ischemia Reperfusion Injury, hypoxia re-oxygenation, Toll like receptors, 
Innate immunity, CLI-095 
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Introduction 
Kidney transplant 
Kidney disease affects 200 million people worldwide, and on average 16 people   
experience kidney failure daily in Canada alone [1]. Transplant remains the best option 
for patients suffering from end-stage renal disease [2]. However, chronic allograft 
rejection and side effects of immunosuppressive drugs are still a barrier to the long-term 
success of kidney transplant. Many studies have linked acute kidney injury, delayed graft 
function, and acute and chronic rejection to the damage incurred by ischemia reperfusion 
injury (IRI) during and after the transplant [3]. 
1.1.1 IRI and transplant 
IRI often occurs when transplanting a kidney and is the result of a disturbance of 
the blood flow. Brain death influences disturbance of blood flow and is caused by chronic 
hemodynamic interruptions in the cadaveric donors. The innate immune system and 
complement cascade in the donor are activated by these disturbances. During the 
harvesting operation, a brief but chronic renal ischemia is caused by clamping of the 
renal artery. Further ischemia damage may result from cold ischemia during storage of 
the allograft kidney [4]. In living donors, there is subjection of the allograft kidney 
transplantation into warm ischemia, where there are no condition interruptions relating to 
brain death. However, IRI is less severe in living donor’s transplantation [5]. 
1.1.2 Delayed graft function and IRI 
After the transplantation of the kidney, another often early condition is delayed 
graft function (DGF), which is occures after ischemic acute tubular necrosis as a result of 
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IRI [6]. The level of IRI is dependent on many factors occurring in the donor, the 
transplantation process, and the recipient [7]. The first post-transplant period is when the 
severe complication DGF occurs. Based on the severe complications relating to the renal 
impairment and the related costs of longer hospital periods, many studies have linked 
DGF occurrence and the acute and chronic allograft dysfunction [8, 9]. A two-phase 
injury is determined by IRI in the transplanted kidney. The initial phase, occurring 
immediately after transplantation, is linked to the ischemic damage, while the second 
phase, which happens later, is associated with IRI-linked activation of the adaptive and 
innate immune response. It has the capacity to influence either cell-mediated rejection or 
antibody-mediated rejection (ABMR) [10, 11]. 
The following factors affect DGF and IRI. (I) Donor factors: Donor-associated 
factors that increase DGF risks are donor age, results of biopsy at implantation, and brain 
or cardiac death [12, 13]. (II) Recipient factors: The significant recipient factors that 
influence the occurrence and severity of DGF and IRI are high panel-reactive antibodies, 
a body mass index higher than 30, the African American race, and the male gender [14]. 
(III) Storage preservation: The duration of cold ischemia and storage time is related to 
DGF. Sufficient preservation of renal allograft is essential during cold storage for 
prevention of DGF [15, 16]. 
The clinical influence of IRI on the rate of survival and kidney graft function is 
related to DGF, rejection of the graft, and severe graft dysfunction with a continuous 
interstitial fibrosis. (I) DGF: DGF is caused by IRI-linked ischemic graft damage, which 
affects the long-term and short-term results of the kidney graft [17]. There is a lack of a 
basic DGF definition, and controversy exists regarding the effect of DGF on long-term 
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graft survival. (II) Graft rejection:  After kidney transplantation, the inflammatory 
response following IRI leads to a higher immunogenicity of the graft [18]. IRI may also 
increase the response of humoral immunity to antigens. An enabled cross relation 
between B and T cells also favors this increase. This results in increased rates of ABMR. 
Furthermore, immunogenicity of the graft is enhanced by the presentation of antigens by 
dendritic cells to the naive T cells, hence causing rejections of T cells [19]. (III) Chronic 
graft dysfunction: Continuous interstitial fibrosis of the kidney graft is caused by IRI in 
experimental models of kidney transplantation. In humans, in contrast, IRI is associated 
with the establishment of interstitial fibrosis or tubular atrophy [20, 21].  
IRI 
IRI is a common cause of acute kidney damage and has an impact on both short- 
and long-term graft survival post-transplant [22]. Ischemia refers to the restriction of 
blood to body tissues, which results in shortages of the oxygen and glucose necessary for 
cell metabolism. There are instances in which blood flow returns to affected tissues after 
an ischemic period, and damage that occurs during this period is referred to as 
reperfusion injury [23]. A decreased metabolic supply in an ischemic organ leads to 
severe microvascular dysfunction [24]. Interestingly, reperfusion does not reinstate 
normal circumstances, but instead increases the injury by activating numerous 
mechanisms, such as innate and adaptive immune activation and cell death programs 
[25].  
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1.2.1 Kidney IRI pathophysiology 
1.2.2 Oxidative stress and mitochondrial dysfunction 
The first change stimulated by ischemia is a shortage in oxygen availability, 
which leads to a change from aerobic to anaerobic metabolism [26]. The latter does not 
satisfy the demand from aerobic tissues, and intracellular ATP levels therefore decrease. 
In addition, intracellular acidosis increases due to increased lactic acid, which results 
from lactate-dependent ATP creation. These procedures result in (1) destabilization of 
lysosome membranes with lysosome enzyme leakage and cell structure breakdown [27]; 
and (2) inhibition of membrane-bound Na+-K+-ATPase action [28]. Eventually there is a 
huge intracellular release of Na+ ions and water, along with edema [26]. The levels of 
intracellular Ca2+ also increase because it is no longer being pumped out of the cells [29] 
and the depletion of ATP prevents Ca2+ re-uptake [30]. In turn, the overproduction of 
calcium leads to the stimulation of calcium-dependent proteases such as calpains. 
Calpains stay inactive because of the acid environment, although they might harm the 
cells after the normalization of pH upon reperfusion [31]. Another consequence of 
Ca2+ overproduction is the production of reactive oxygen species (ROS) in the 
mitochondrial stage of ischemia. This leads to the opening of mitochondrial transition 
pores (mPTPs) after reperfusion, along with cell death and apoptosis [32, 33].  
1.2.3 Inflammation  
 Based on observations of abnormities in kidney IRI, inflammation appears to link 
different types of cells and is important in the pathophysiology. An inflammatory cascade 
in renal IRI can result in further damages. Therefore, renal tissue is protected by the 
inhibition of inflammatory response as a key therapeutic tactic [34, 35]. The key 
inflammation mediators are chemokines, cytokines, and interleukins, which have a major 
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role in regulating pro-inflammatory reaction, infiltration, and activation of leukocytes, as 
well as the expression of adhesion molecules [36]. Renal dysfunction is highly stimulated 
by pro-inflammatory cytokines such as interleukin 6 (IL6) and TNFα [36, 37]. 
 Neutrophils and leukocytes are recruited into post-ischemic tissue by 
inflammatory mediators, ROS, and cell adhesion molecules P-selectin and intracellular 
adhesion molecule-1 (ICM-1). This later results in improved leukocyte-endothelial 
interactions, which can increase damage to and inflammation of the endothelial cells, and 
interfere with blood flow[38]. Both chronic and acute renal failure have been associated 
with the participation of the inflammatory leukotriene pathway in IRI [39, 40]. In 
summary, it is evident that inflammation, leukocytes, and adhesion molecules are 
extremely integrated with the process of IRI. Thus, any agents capable of inhibiting 
neutrophils and leucocyte infiltration or suppressing inflammation could be able to 
reduce the effects of IRI on the kidney. 
1.3 Innate and adaptive immunity 
The innate immune system comprises the initial line of host defense throughout 
infection. It therefore plays a decisive role during early detection and consequent 
activation of pro-inflammatory reactions to attacking pathogens [41]. Conversely, the 
adaptive immune mechanism is responsible for the eradication of pathogens during the 
late stage of infection and during the production of immunological memory [42]. 
 The innate immune system consists of cellular and non-cellular components that 
react instantly and non-particularly to microorganisms at the spot of infection. The 
cellular elements of innate immunity include macrophages, neutrophils, dendritic cells 
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(DCs), and natural killer (NK) cells [43]. The molecular elements include toll-like 
receptors (TLR), chemokines, complement proteins, and cytokines [44, 45].  Due to IRI, 
innate elements are stimulated (complement activation and TLR triggering) [46], and 
these activate adaptive immunity and add to the delay of graft functions. In contrast, the 
adaptive immune system consists of an antigen-specific immune reaction against an 
identified foreign antibody and leads to memory. The adaptive system is further separated 
into cell-mediated immunity and humoral immunity, which involve antibody-releasing B 
cells and cytotoxic/helper T cells, respectively. 
1.3.1 Cells involved in innate immunity 
After reperfusion, neutrophils adhere to the endothelium and drift into the tissue. 
The neutrophils respond to any unspecific injuries and discharge proteases, ROS, and 
pro-inflammatory cytokines, such as IL-4, IL-6, interferon-γ, and tumor necrosis factor-α 
[47]. Macrophages also generate pro-inflammatory cytokines and can be found in injured 
tissues from the early phases of IRI [48]. The NK cells serve vital roles in renal IRI, 
including the perforin-dependent killing of tubular cells [49]. DCs represent a necessary 
stage during the pathogenesis of IRI and experience an antigen-independent maturation 
process stimulated by damage-associated or pathogen-associated molecular proteins 
(DAMPs, PAMPs). In addition, DCs can symbolize a bridge between innate and adaptive 
immune stimulation. In renal transplantation, brain death induces oxidative stress in the 
deceased donor. The donor DCs are stimulated in this case and can trigger the recipient’s 
T cells [50].  
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1.3.2 Kidney DCs 
Kidney DCs are present in the interstitial extracellular compartment and are 
perfectly located to interact with other substances that are transported from the tubule 
lumen and directly into the peritubular capillaries [51]. These DCs also interact with 
endogenous molecules, exogenous invading organisms, lymphocytes, NK T cells, 
fibroblasts, and epithelial cells. Therefore, DCs are activated by DAMPs or PAMPs [52]. 
If these two molecular patterns are present, then the DCs act as key effectors and 
initiators of the innate immune system, which comprises NK cells, DCs, monocytes, and 
neutrophils. In reperfusion damage from kidney ischemia, the kidney DCs play an 
integral role in the antigen-independent inflammatory response after reperfusion has 
taken place. They also play a substantial role in the production of chemokines and 
cytokines, and both of these signaling proteins drive neutrophil infiltration through the 
processes of activating NK T cells and the signal pathway [48, 53]. 
At the same time, DCs can also stimulate tolerance due to the phenotypic 
plasticity and function of the kidney. The kidney DCs that induce tolerance are immature, 
insufficiently produce positive co-stimulatory signals, and inadequately enhance negative 
stimulatory signals. They also express reduced pro-inflammatory cytokines and have the 
capacity to produce immune tolerance via induced T cell energy. 
 1.3.3 Formation and maturation of DCs 
DCs are extracted from bone-marrow hematopoietic cells. They initially 
transform into immature DCs and are characterized by low T cell activation potential and 
high endocytic activity. Immature kidney DCs continuously sample their environment for 
bacteria, viruses, and other pathogens. They do this via pattern-recognition receptors, one 
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of which is TLR4. Immature DCs use phagocytose nominal amounts of the membranes of 
live cells, which is also known as nibbling. When these immature cells interact with a 
presentable antigen, the cells turn into DCs and then travel themselves to a lymph node.  
The cells also phagocytose different pathogens and extract their proteins in tiny 
pieces. Once these cells have matured, they present fragments at the cell surface via 
MHC. These cells simultaneously enhance the ability to activate T cells and upregulate 
co-receptors for the purpose of T cell activation, such as CD40, CD86, and CD80. 
Moreover, these cells also regulate chemokine receptor type 7, which is a chemotactic 
receptor that causes DCs to travel via the blood stream or the lymphatic system. This is 
where they play the role of antigen-presenting cells, which trigger helper and killer T 
cells. Furthermore, they activate B cells by providing them with different antigens that 
are extracted from a pathogen and co-stimulatory signals. These cells can also activate T 
cell tolerance and some C-type lectin receptors, which function as pattern-recognition 
receptors and regulate DCs when lymphocyte activation is appropriate instead of 
inducing immune tolerance [54]. 
Helper T cells are limited to a single antigen and are professional antigen-
presenting cells like DCs. These cells can activate resting helper T cells when the 
corresponding antigen is provided. B cells and macrophages have the capacity to activate 
memory T cells, while DCs can activate both naïve T cells and memory T cells. Naïve T 
cells and memory T cells are some of the most potent among antigen cells. Mature DCs 
have the potential to activate CD8± T cells, while the formulation of memory T cells can 
only be completed by the interaction of CD4 helper T cells and DCs [55]. The help 
provided by CD4 cells subsequently triggers the matured cells and induces CD8 memory 
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T cells, which have the capacity to expand twice [55, 56]. This activation process 
requires simultaneous interaction from CD8 T cells, CD4 DCs, and T cells [56]. 
As previously mentioned, mature DCs are generated from white blood cells and 
monocytes, which can transform into DCs or macrophages. The macrophages are formed 
from stem cells in bone marrow, whereas monocyte DCs are produced through peripheral 
blood mononuclear cells (PBMCs). These monocytes can be treated with interleukin and 
granulocyte macrophage colony-stimulating factor, both of which result in the 
differentiation of immature DCs in approximately one week’s time. After this treatment, 
tumor necrosis factor then turns the immature DCs into mature DCs [57].  
1.3.4 Mechanism of IRI-induced immune system activation 
There are two stages in the sequence caused by ischemia reperfusion and the 
resulting immune system activation. The first is the stimulation of the innate system. The 
detection receptors of innate immunity are mainly TLRs (both intra- and extracellular), 
NOD-like receptors, intracellular receptors, and retinoic acid-inducible gene 1 receptor 
(RIG1). TLRs are necessary to identify PAMPs or DAMPs. The TLRs trigger several 
kinases [IL-1-receptor-linked kinase 1 (IRAK1), IL-1-receptor-linked kinase 4 (IRAK4), 
TANK fastening kinase 1, inhibitor of NF-κB kinase] enlisting within the cytoplasm 
adaptor fragments [myeloid separation 88 (MyD88), Toll/IL receptor-containing adaptor 
protein, TRIF-related adaptor molecule, and TIR domain-containing adaptor-inducing 
interferon (TRIF)]. The kinases intensify and broadcast the signal to the transcription 
elements NF-κB, MAP3 kinase (MAPK3), and interferon regulatory element 3. Finally, 
the transcription elements program the genes controlling the inflammatory cells  [9]. 
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The second stage is the stimulation of the adaptive mechanism. In tissues 
influenced by inflammation, the immature DCs develop into mature cells, attach to the 
antigen, and drift to the lymph nodes, where they present the antigen to the T cells. The T 
cell activation is mediated through signals produced by the T cell receptor and the co-
activation fragments. The strict relations between T and B cells might produce an 
alloimmune reaction. It has also been established that the renal IRI might increase the 
humoral immune reaction and produce an ABMR  [11]. 
 
Figure 1: The mechanism of IRI-induced immune system activation 
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  1.4 TLRs 
TLRs are germline-encoded pattern-recognition receptors that detect invading 
pathogens in the host immune system [58]. To date, 10 TLRs have been defined in 
humans, while mice have 12 [58]. TLRs are types of transmembrane proteins that are 
expressed primarily in the immune system cells, such as macrophages, DCs, neutrophils, 
B cells, and NK cells [59-61]. However, TLRs can also be expressed in non-immune 
cells, such as epithelial and endothelial cells [61]. Signaling via TLRs depends on 
association with a group of cytoplasmic adaptor molecules, principally MyD88 and 
Toll/IL-1 receptor domains containing adaptor-inducing IFN-β (TRIF) [62]. Upon 
activation via MyD88, TLRs initiate downstream signals that liberate transcription factor 
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) to be translocated 
to the nucleus. This in turn initiates the transcription of pro-inflammatory cytokines, 
chemokines, and adhesion molecules, as well as neutrophil infiltration in graft tissue and 
DC maturation [60]. Moreover, mature DCs interact with T cells and promote the 
adaptive immune response [63]. In the context of transplantation, TLR-driven innate 
immune responses are critical to IRI. 
1.4.1 TLRs ligands 
TLR receptors recognize microbial products such as bacterial lipopolysaccharides 
(LPS) and CpG DNA. These are also known as PAMPs. Endogenous ligands released 
from damaged tissues known as DAMPs can also signal through TLRs. These include 
high-mobility group box 1 (HMGB-1), heat shock proteins, and necrotic nucleosome-
DNA, which can be recognized by TLR2, TLR3, TLR4, and TLR9 to promote 
inflammation [60, 64, 65]. Among them, only the nuclear protein HMGB-1 has been 
12 
 
confirmed to be related to the pathogenesis of IRI [66, 67]. HMGB-1 unites the DNA and 
controls the transcription and modeling of chromatin. In deceased-donor kidneys, in 
which IRI is recurrent and severe, TLR-4 is upregulated and tubular HMGB-1 is 
noticeable [68]. The TLR4 receptors play a major role in IRI. 
1.4.2 HMGB-1 
The chromatin-linked protein HMGB-1 is released by hematopoietic cells via 
a lysosome-mediated pathway [69]. It is a key mediator of endotoxin shock [70] and 
serves in numerous immune cells to activate inflammatory reactions as a DAMP [71]. 
Recognized receptors for HMGB-1 include TLR2, TLR4, and RAGE (receptor for 
advanced glycation end products). HMGB1 can stimulate maturation of dendritic cell 
through upregulation of CD80, CD83, CD86, and CD11c; and stimulate creation of other 
pro-inflammatory cytokines within myeloid cells (IL-1, TNF-α, IL-6, IL-8), including 
upregulated articulation of cell adhesion particles (ICAM-1, VCAM-1) on endothelial 
cells. 
1.4.3 TLRs’ signaling pathway 
The innate immune system uses TLRs to identify preserved molecules connected 
with pathogens, resulting in inflammatory reactions and a link to adaptive immunity [72, 
73]. Upon binding to the conventional TLR ligands, all of the TLRs apart from TLR3 
employ the adaptor particle MyD88 via the TIR domain and arbitrate the MyD88-
dependent pathway [74]. After that, MyD88 employs the serine-threonine kinases IL-1, 
receptor-linked kinase4 (IRAK4), and IRAK1. IRAK4 phosphorylates IRAK1 and 
subsequently mediates the employment of TRAF6 by the receptor compound [75]. The 
IRAK1-TRAF6 compound then detaches from the receptor to interact with and stimulate 
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MEKK3 and TAK1, which are members of the MAP kinase kinase kinase (MAPKKK) 
family [76]. The activation of TAK1 and MEKK3 ultimately stimulates of NF-κB and 
JNK [77], which results in the transcription of chemokine genes and inflammatory 
cytokines such as those encoding TNFα, IL-1β, IL-6, and IL-8. Moreover, TLR3 and 
TLR4 recruit a MyD88-independent pathway that employs TIR domain-containing 
adaptor stimulating IFN-β (TRIF) to stimulate NF-kB and IRF3. 
1.4.4 TLR4 and IRI 
Several studies have suggested that the expression of both TLR4 and its multiple 
endogenous ligands is amplified in the ischemic kidney in response to the devolvement of 
renal IRI signaling through the TLR4/MyD88 pathway [78-80]. In one study, mice 
hereditarily lacking in TLR4 were protected from kidney dysfunction and histological 
harm. This protection was linked with a decrease in pro-inflammatory cytokine and 
chemokine production associated with the reduction of macrophage and neutrophil 
infiltration. TLR4 signaling in kidney parenchymal cells significantly contributes to 
kidney damage, although articulation of TLR4 on leukocytes is also clearly significant in 
IRI [78]. This underlines the role of TLR4 in renal ischemia reperfusion, and suggests 
that blocking TLR4 signaling might offer a foundation for therapeutic strategies to 
diagnose or protect against renal ischemic damage. 
1.5 Therapeutic targeting of TLRs 
Research using TLR-deficient mice has implied a role of TLRs in several 
pathological circumstances, and the topic of TLRs and the signals they produce is 
attracting huge interest. A majority of the research has been conducted using different 
ischemia reperfusion models, such as intestinal, renal, hepatic, cerebral, and myocardial 
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models. Such studies have also focused on the functionality of TLR4 to various degrees. 
Moreover, TLR4 is also thought to be engaged in numerous pathologies, such as cardiac 
diseases [81], sepsis [82], and IRI [83-85]. Therefore, TLR4 is a notable therapeutic 
target for the management of inflammatory diseases. In this vein, numerous small-
molecule complexes that control TLR signaling were explored in a clinical study [86].  
1.5.1 CLI-095 
CLI-095 is a cyclohexene derivative that is also known as TAK-242. It is an 
antagonist for TLR4 and selectively inhibits its pathway [87]. CLI-095 was initially 
categorized as a suppressor of nitric oxide (NO) and cytokine generation by LPS-
stimulated macrophages and in endotoxin shock in mice [88]. CLI-095 attaches to 
cysteine 747 in the intracellular sphere of TLR4, thus hindering both MyD88-
independent and MyD88-dependent pathways stimulated by LPS [89]. Furthermore, one 
study demonstrated that CLI-095 suppresses LPS-induced inflammation [90]: CLI-095 
restrains the production of TNF-α in LPS-activated human U-937, mouse RAW264.7, 
and P31/FUJ cells [90]. Moreover, CLI-095 hinders the stimulation of ligand-
independent NF-κB, resulting in overexpression of TLR4. CLI-095 also suppresses the 
linking of Toll/interleukin-1 together with the TLR4 receptor domain, consisting of an 
adaptor protein. Furthermore, CLI-095 inhibits the activation of TIRAP-mediated nuclear 
factor and activates TRAM-mediated and interferon-sensitive components in HEK293 
cells articulating MD-2, CD14, and TLR4 [91]. In addition, in one study CLI-095 
management hindered IRAK1 stimulation in RAW264.7 cells. Furthermore, a study 
carried out on a cerebral ischemia reperfusion model established that CLI-095 
considerably decreased cerebral infarction, enhanced neurological function, hindered the 
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phosphorylation of downstream protein kinases in the TLR4 signaling pathway, and 
down-regulated the articulation of inflammatory cytokines [92]. 
 
Figure 2: CLI-095 structure 
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Figure 3 (A) TLR4 signaling pathway (B) CLI-095 mechanism of action on TLR4. 
The TLR4 pathway transduces signaling in both MyD88-dependent and TRIF-
dependent pathways (MyD88 independent). CLI-095 interferes with and blocks the 
interaction between TLR4 and its adaptor molecules [93]. 
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1.6 Rationale and hypothesis 
1.6.1 Rationale  
In one study, RAG-1-deficient mice lacking both T and B cells were not protected 
from IRI, suggesting that cells of the innate immune system (such as DCs) play a 
significant role [94]. In fact, DCs are the first responders to DAMPs released from 
damaged or necrotic cells after oxygen deprivation, with subsequent activation of TLR4 
and TLR9 signaling. In contrast, DCs significantly infiltrate the kidney after IRI [95]. 
These findings suggest that it is important to determine whether CLI-095 can modulate 
TLR4 signaling in DCs to reduce activation of innate immune response to re-oxygenation 
after hypoxia. 
1.6.2 Hypothesis 
We hypothesize that TLR4 signaling plays an important role in the activation of 
innate immunity, and that targeting its pathway will prevent innate immunity activation 
in response to re-oxygenation after hypoxia. 
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2 Material and methods 
2.1 Cell culture methods  
Maintenance of cell lines. Dulbecco’s modified Eagle medium (DMEM; Corning 
cellgro), supplemented with 10% fetal calf serum (FCS; Gibco) and 1.1% penicillin-
streptomycin (Gibco), was used to maintain RAW 264.7 cells. The cells were kept in a 
humidified incubator (37oC; 5% CO2).  
Cell culture. For passaging, adherent cells were washed with pre-warmed (37oC) 
1X PBS (Gibco), sub-cultured using 5 mL 0.25% trypsin, and stored in a 37°C incubator 
for 5 min. Trypsin dilution was performed by adding the appropriate cell medium, which 
was then pooled into 50-mL tubes. Cells were pelleted by centrifugation (1,000 rpm; 5 
min) at room temperature. For washing, the cells were re-suspended in appropriate cell 
media and centrifuged (1,000 rpm; 5 min) at room temperature. The pelleted cells were 
re-suspended in the appropriate cell medium and re-plated on 12-well plates at the 
required density (1 × 106 cells/well).  
Primary cells: isolation of bone-marrow-derived DCs. Femurs of C57BL/6 mice 
were removed and freed from tendons and muscles. The bones were placed in 70% 
ethanol for 2 min and then washed in DMEM. The bone ends were cut off, and DMEM 
was used to flush out the marrow. The isolated cells were centrifuged (1,000 rpm; 5 min), 
and then cultured in a six-well dish at a density of 1x106 cells/mL in DMEM with 1% L-
glutamine (Gibco), 1.1% penicillin-streptomycin, and 10% FBS. The cells were then 
supplemented with 20-30 ng/mL of mouse granulocyte-macrophage colony-stimulating 
factor (mGM-CSF). Half of the medium was replaced by fresh medium on day 3 of 
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culture. On day 5, the medium was completely replaced with fresh medium. On day 6, 
the medium was removed, and cells were incubated with Accutase (Innovation Cell 
Technologies) at 25°C for 15 min. Cells were pooled into 50-mL tubes and were pelleted 
by centrifugation (500 rpm; 5 min) at room temperature. The pelleted cells were re-
suspended in DC medium and re-plated on 12-well plates at the required density (1 × 106 
cells/well).  
2.2 Experiment design  
2.2.1 Incubation with LPS 
DCs that were plated on 12-well plates (1 × 106 cells/well) were divided into four 
groups of three wells each. Group 1, the normal cells, comprised untreated DCs that were 
incubated for 12 hrs. Group 2, the LPS cells, were treated with 50 ng/ml of LPS for 12 
hrs. Group 3, the CLI-095 group, included cells treated with 100 µg/ml of CLI-095 
(Invivogen) 3 hrs before the end of the incubation time (12 hrs). Group 4, the CLI-
095+LPS group, comprised cells that were treated with CLI-095 for 3 hrs and then 
incubated with LPS for 12 hrs. At the end of the incubation time, cell-culture 
supernatants were collected for ELISA, and the cells were obtained for PCR and flow 
cytometry studies. 
2.2.2 Hypoxia, re-oxygenation, and incubation 
DCs that were plated on 12-well plates (1 × 106 cells/well) were divided into two 
groups of six wells each. Group 1, the hypoxia group, included cells that were incubated 
without treatment, and group 2, the CLI-095+hypoxia group, comprised cells treated with 
100 µg/ml of CLI-095 before incubation. Media were replaced by DMEM (glucose- and 
FBS-free media); 1 ml was used for each well, and then cells were incubated for 12 hrs in 
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a hypoxic environment using a GENbag anaer (bioMerieux® sa, Marcy I’Etoile, France; 
2% O2). After 12 hrs, the media were replaced by warm DC media, and the cells were 
incubated in normal conditions for 12 hrs (re-oxygenation). At the end of the incubation 
time, the cell-culture supernatants were collected for ELISA, and the cells were obtained 
for PCR and flow cytometry studies. 
2.2.3 Normoxia incubation 
DCs in 12 wells (1 × 106 cells/well) were divided into two groups. In group 1, the 
normoxia group, cells were incubated without treatment, and in group 2, the CLI-095 
group, cells were treated with 100 µg/ml of CLI-095 before incubation. Cells were 
incubated for 24 hrs at 37oC. At the end of the incubation time, the cell-culture 
supernatants were collected for ELISA, and the cells were obtained for PCR and flow 
cytometry studies.  
2.2.4 Nucleic acids 
Extraction of nucleic acids 
The mRNA was extracted from cultured cells according to the protocol supplied 
with the PureLink RNA Mini Kit (Thermo Fisher Scientific). A NanoDrop ND-1000 
(Thermo Fisher Scientific) was employed to determine the concentration of RNA 
samples. 
cDNA synthesis 
To synthesize cDNA, 0.5-1.0 µg of RNA and 4 µl of SuperScript VILO Master 
Mix (Thermo Fisher Scientific) with 20 μL of H2O were incubated at 25oC for 10 min. 
The reaction was carried out in a thermocycler (Eppendorf Mastercycler) with the 
following parameters: 25 °C for 10 min, 42°C for 1 hr, 80°C for 5 min, and holding at 
25°C. The concentration of cDNA samples was determined using a NanoDrop ND-1000. 
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Real-time PCR 
The mRNA expressions of TLR4, MyD88, IRAK4, NF-kB, and β-actin (Sigma) 
were determined using real-time PCR. Each cDNA sample was amplified using SYBR 
Green (Bioline) on a Bio-Rad CFX Connect Real-Time PCR System. Briefly, the 
reaction conditions comprised 2 μl of cDNA and 0.2 μM primers in supermix with a final 
volume of 20 μl. Each cycle comprised denaturation at 95°C for 5 sec, annealing at 60°C 
for 30 sec, and extension at 72°C for 10 sec. β-actin was used as an endogenous control 
to normalize each sample. Fold changes were calculated using the ΔΔCT method. The 
experiment was performed in triplicate and repeated in five independent trials. Primers 
were purchased from Sigma-Aldrich (ON, Canada) and are listed in Table 1. 
2.2.5 Flow cytometry 
Standard procedures were employed to perform flow cytometry analysis. All 
antibodies were purchased from GeneTex, Inc. The following antibodies were used: 
CD11c-FITC, MHCII-FITC, CD80-FITC, CD83-FITC, and CD86-FITC. The cells were 
washed, and the cell numbers were adjusted to 1-5 x 106 cells/mL in an ice-cold 
Fluorescence-Assisted Cell-Sorting (FACS) buffer, which contained PBS, 0.1% NaN3 
(Sigma), and 5-10% FBS. The cells were incubated with 2% FC blocker for 20 min, and 
subsequently centrifuged (1,200 rpm; 5 min; 4°C), followed by resuspension in FACS 
buffer. The cells were then incubated with 0.1-10 μg/mL of primary labeled-antibody in 
the dark for 45 min at 4°C and washed twice with FACS buffer. The cells were analyzed 
using a CytoFLEX Flow Cytometer (Beckman-Coulter) and treated with 7-
AminoActinomycin D (7- AAD; BD Via-Probe) for 10 min to identify dead cells. They 
were then passed through Nitex into an FACS tube before analysis to avoid any 
remaining clumps. 
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2.2.6 ELISA 
The amount of cytokine proteins secreted in the cell culture media was 
determined using IL-6 and TNF ELISA kits (BioLegend). To obtain culture supernatants, 
each cell culture (1 × 106 cells/well) was grown alone and together on 12-well plates (1 
mL/well). The resulting cell-cultured media supernatant was harvested and centrifuged to 
remove cellular debris. Cytokines in the cell-culture supernatant were measured using 
ELISA kits according to the manufacturer’s instructions. The cytokine protein levels 
were corrected for the total amount of proteins, and the results are expressed in pg/mL. 
The absorbance was read at 450 nm and 570 nm using an iMark Microplate Absorbance 
Reader (Bio-Rad), and the concentration of the samples was determined using a standard 
curve. 
2.3 Statistical analysis 
For all the experiments, statistical analysis was done using GraphPad Prism 6 and 
Microsoft Excel 2010 software. The results are expressed as the standard deviation (SD) 
of at least three technical and biological replicates. An unpaired student’s t-test was used 
to determine the statistical significance. A two-way ANOVA followed by a post-hoc 
Tukey’s test was employed for the analysis of parametric data. P-values < 0.05 were 
considered statistically significant. 
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Table 1: List of primers 
PRIME
R 
Forward Reverse  
TLR4 AACTCTGGATCTACCCTTTC AAAGCTCAGTGCATTTCTAC 
MyD88 TATACTGAAGGAGCTGAAGTC TAAAGGCATCGAAAAGTTCC 
IRAK4 CTGCCTTGTTTATGGCTTCTTG AGAAGAATGTCCAGTCGTTGA
G 
NF-κB CCTTCCTCAACTTCCAGAACA
A 
CCTTCTCTCTGTGTGTGAGTTG 
B-Actin GATGTATGAAGGCTTTGGTC TGTGCACTTTTATTGGTCTC 
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3 Results 
The objective of the present study is to evaluate the role of CLI-095 in reducing 
the TLR4-mediated innate immune response to hypoxia and re-oxygenation injury. In our 
in vitro model, we were able to induce this injury and assess its effects on DC maturation. 
We were also able to evaluate the effect of CLI-095 on the early events in TLR4 
signaling. In addition, CLI-095 reduced the levels of DC maturation markers and pro-
inflammatory cytokines in response to the injury. 
3.1 CLI-095 binds to TLR4 and blocks the TLR4 signaling 
pathway 
We tracked the TLR4 signaling pathway to define the mechanism behind the 
ability of CLI-095 to reduce the innate immune response. We examined the mRNA 
expression of two mediators of the TLR4 signal: NF-kB and IRAK4. IRAK4 is an 
essential activator of NF-κB, and NF-κB is a protein complex that controls DNA 
transcription, cytokine production, and cell survival. The cells were subjected to hypoxia 
and re-oxygenation, and then compared to CLI-095-treated cells, which were incubated 
with CLI-095 for 3 hrs and then also subjected to hypoxia and re-oxygenation. IRAK4 
and NF-κB expression levels were greatly reduced in CLI-095-treated cells compared to 
untreated cells, indicating that CLI-095 can block the TLR4 signal. 
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Figure 4: Expression of IRAK4 and NF-κB mRNA in DCs incubated in normal 
conditions (normoxia), hypoxia, and re-oxygenation (hypoxia), and cells treated 
with CLI-095 (100 μg/ml) for 3 hrs and then subjected to hypoxia and re-
oxygenation (CLI-095 hypoxia). 
DCs were subjected to hypoxia for 12 hrs and then re-oxygenated for 12 hrs. 
IRAK4 and NF-κB expression levels were compared to those of untreated cells 
(normoxia) and cells treated with CLI-095 (100 μg/ml) for 3 hrs and then subjected to 
hypoxia and re-oxygenation. Relative levels of NF-κB and IRAK4 mRNA were 
normalized to β-actin and the normal sample’s mRNA. Error bars represent SD, n=3. 
**** p < 0.0001.  
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3.2 CLI-095 attenuated the expression of inflammatory 
mediators in innate immune cells 
3.2.1 CLI-095’s protective effects on DC pro-inflammatory cytokines 
in response to hypoxia re-oxygenation injury 
Cells injured by hypoxia and re-oxygenation that were treated with CLI-095 
showed reduced levels of pro-inflammatory cytokines (TNFα and IL6) compared to cells 
that were only subjected to hypoxia and re-oxygenation injury (Fig. 5).  
3.2.2 CLI095’s protective effects on the RAW264.7 cell line’s levels of 
pro-inflammatory cytokines in response to LPS and hypoxia re-
oxygenation injury 
To determine whether CLI-095 could reduce the levels of pro-inflammatory 
cytokines in other innate immune cells, we demonstrated that RAW cells subjected to 
hypoxia re-oxygenation injury showed the same result as DC cells in the same incubation 
conditions (Figure 6).  
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Figure 5: Cytokine production by DCs incubated in normal conditions (normoxia), 
hypoxia, and re-oxygenation (hypoxia), and cells that were treated with CLI-095 
(100 μg/ml) for 3 hrs and then subjected to hypoxia and re-oxygenation (CLI-
095+hypoxia). 
DCs were subjected to hypoxia for 12 hrs and then re-oxygenated for 12 hrs. 
Subsequent cytokine production was compared to that of untreated cells (normoxia) and 
cells treated with CLI-095 (100 μg/ml) for 3 hrs and then subjected to hypoxia and re-
oxygenation. The culture media were collected, and IL6 (A) and TNF-α (B) were 
quantified by ELISA. Results are expressed as mean pg/ml ± SE from four independent 
experiments. Cells treated with CLI-095 showed reductions in pro-inflammatory cytokine 
levels (TNFα and IL6) compared to cells that were only subjected to hypoxia and re-
oxygenation. * p < 0.05, ** p < 0.002, *** p < 0.001, **** p < 0.0001. 
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Figure 6: Cytokine production by RAW264.7 cells incubated in normal conditions 
(normoxia), hypoxia, and re-oxygenation (hypoxia), and cells treated with CLI095 
(100 μg/ml) for 3 hrs then subjected to hypoxia re-oxygenation (CLI-095+hypoxia). 
RAW cells were subjected to hypoxia for 24 hrs and then re-oxygenated for 24 
hrs; subsequent cytokine production was compared to that of untreated cells (normoxia) 
and cells treated with CLI-095 (100 μg/ml) for 3 hrs then subjected to hypoxia re-
oxygenation. The culture media were collected and IL6 (A) and TNF-α (B) were 
quantified by ELISA. Results are expressed as mean pg/ml ± SE from three independent 
experiments. Cells treated with CLI-095 showed reductions in pro-inflammatory cytokine 
levels (TNFα and IL6) compared to cells that were only subjected to hypoxia re-
oxygenation. * p < 0.05, ** p < 0.002, *** p < 0.001, **** p < 0.0001. 
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3.3 DC maturation marker activation after hypoxia and re-
oxygenation injury 
3.3.1 Cell maturation in response to hypoxia and re-oxygenation 
To assess the ability of damaged cells to induce DC maturation in response to 
hypoxia and re-oxygenation, DCs were subjected to hypoxia for 12 hrs, followed by re-
oxygenation for 12 hrs. Afterwards, we examined DC maturation markers (MHCII, 
CD80, CD83, and CD86) using flow cytometry. MHCII, CD80, CD83, and CD86 
increased in samples without treatment compared to non-hypoxic cells that were kept for 
24 hrs in normal culture conditions (Figure 4). 
3.3.2 CLI-095’s protective effects on DC maturation in response to 
hypoxia and re-oxygenation injury 
Cells treated with 100ug/ml of CLI095 3 hrs before hypoxia and re-oxygenation 
showed decreased levels of DC maturation markers (MHCII, CD80, CD83, and CD86) 
compared to untreated hypoxic cells. When compared to non-hypoxic samples, CLI095-
treated cells exposed to hypoxia re-oxygenation injury showed no significant differences, 
indicating the potent protective effects of CLI095 against hypoxia re-oxygenation injury 
(Figures 5 and 6).  
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Figure 7: Analysis of cell surface maturation marker expression in DCs in response 
to hypoxia and re-oxygenation, and CLI-095 treatment 
Histogram of MHCII, CD80, CD83, and CD86 expression in cells subjected to 
hypoxia and re-oxygenation, and CLI-095-treated hypoxia and re-oxygenation cells. The 
percentage represents hypoxia-stained cells in comparison to normoxia-stained cells. 
Histograms are representative of four separate experiments. 
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Figure 8: Analysis of cell surface maturation marker expression in DCs in response 
to hypoxia and re-oxygenation 
Cells subjected to hypoxia and re-oxygenation in comparison to non-hypoxic 
cells. Flow cytometry analysis of MHCII, CD80, CD83, and CD86 showed that hypoxia 
and re-oxygenation significantly increased the expression levels of MHCII, CD80, CD83, 
and CD86. Results are representative of four different experiments. Error bars represent 
SD, * p < 0.05, *** p < 0.001. 
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Figure 9: Analysis of cell surface maturation marker expression in DCs in response 
to hypoxia and re-oxygenation, and CLI-095 treatment 
Cells subjected to hypoxia and re-oxygenation were compared to CLI-095-treated 
cells incubated with CLI-095 for 3 hrs and then subjected to hypoxia and re-oxygenation. 
Flow cytometry analysis of MHCII, CD80, CD83, and CD86 showed that CLI-095 
treatment before hypoxia and re-oxygenation significantly reduced MHCII, CD80, and 
CD86 levels compared to untreated stressed cells. Results are representative of four 
different experiments. Error bars represent SD, * p < 0.05, ** p < 0.002, *** p < 0.001. 
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4 Discussion 
IRI is an inevitable consequence of kidney transplant and is the primary cause of 
reduced graft survival after transplantation [22, 46]. IRI activates innate immune 
response, which in turn results in varying degrees of tissue damage [61]. The immune 
response occurs when a group of receptors known as TLRs (mainly TLR4) become 
activated after IRI. In microbial infections, TLRs recognize multiple molecules arises 
from microbes collectively called PAMPs. Similarly, molecules secreted from damaged 
cells (DAMPs) can also activate endogenous TLR in sterile conditions, and these 
molecules are also known to trigger innate immune responses and to increase the 
transcription of pro-inflammatory cytokines, chemokines, and adhesion molecules, as 
well as neutrophil infiltration in the graft. Antigenic mimicking of DAMPs helps in DC 
maturation. All of these processes ultimately induce IRI and subsequently cause allograft 
rejection [60]. 
Mature DCs interact with T cells to promote an adaptive immune response [63]. 
Several studies have demonstrated the implication of TLR4 in activating innate immunity 
in various tissues during IRI, including liver, heart, and kidney tissues. The results 
showed that TLR4–/– mice were protected from hepatic, myocardial, and renal IRI [79, 96, 
97]. Therefore, TLR4 could be an important therapeutic target for the management of 
IRI.   
DCs are important immune cells with a major role in antigen presentation and 
adaptive immunity activation. They have always received significant interest from 
researchers of IRI [98]. In facilitating their role in renal IRI, DCs are first activated, 
which initiates their movement into the lymph nodes and their interaction with both T and 
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B cells. This in turn results in an adaptive immune response [99]. The immune system 
has a combination of cells, tissues, and molecules to protect the body from pathogens and 
toxins. For this process to work efficiently, two major reactions occur: innate immunity 
and adaptive immunity. In the innate and adaptive immune responses to acute IRI, 
neutrophils, DCs, and macrophages play the largest and most important roles [95]. 
Studies on the role of the innate immune cells in renal IRI have shown that mice lacking 
both T and B cells were not protected from IRI, suggesting that cells from the innate 
immune system such as DCs play a significant role [94]. However, due to IRI in the 
kidney, DCs can be activated by resulting DAMPs. When IRI-affected organs are 
transplanted, activation of DCs can initiate the adaptive immune response. In the present 
study, we found that intraperitoneal injection of CLI-095 in the mouse IRI model did not 
decrease the creatinine level in the blood. Therefore, we assume that CLI-095-mediated 
TLR4 abrogation may have little in IRI. However, DCs and macrophages are the most 
common and readily available leukocytes in the kidney, where they play a fundamental 
role. In fact, DCs are the initial responders to DAMPs released from damaged necrotic 
cells after oxygen deprivation with subsequent activation of TLR4 and TLR9 signaling. 
In addition, DCs significantly infiltrate the kidney after IRI [95, 99]. 
CLI-095 is a specific and selective inhibitor of TLR4 signaling. In this study, it 
inhibited the production of cytokines (TNF-α and IL-6) induced by TLR4 ligands. 
Furthermore, in LPS-induced DCs, CLI-095 inhibited both MyD88-dependent and 
independent pathways [100]. A study conducted on RAW264.7 cells and HEK293 
(human embryonic kidney) cells showed similar results [91]. Furthermore, CLI-095 has 
been shown to inhibit the activation of NF-κB in LPS-induced HEK293 cells [101]. 
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However, the effect of CLI-095 on innate immune cells has not yet been tested in 
response to hypoxia and re-oxygenation. Therefore, we tested the ability of CLI-095 to 
inhibit the activation of innate immune cells in response to this condition. 
In this study, a hypoxic culture of immature DCs induced co-stimulatory 
molecules, such as CD80, CD83, CD86, and MHCII (Figure 8). This data suggests that 
hypoxia and re-oxygenation trigger DC maturation. Previous studies on hypoxic culture 
of DCs have shown the same result [102]. However, the protective effect of CLI-095 
occurred only when we treated the cells 3 hrs before the hypoxia and re-oxygenation 
activation (Figure 9). This indicates that blocking the TLR4 signal with CLI-095 reduced 
the DC maturation marker. Moreover, this also suggests that DC maturation requires 
TLR4. 
Cytokines and chemokines are pro-inflammatory mediators that are secreted when 
DCs are activated [103, 104]. The stimulation of DCs with hypoxia and re-oxygenation 
induces these cells to secrete inflammatory cytokines such as TNF-α and IL-6 [105, 106]. 
These are important cytokines that stimulate the immune response and are associated 
with many inflammatory conditions, such as trauma, sepsis, infection, and rheumatoid 
arthritis. In addition, TNF-α and IL-6 are involved in cell proliferation, differentiation, 
and apoptosis. Upregulation of TNF-α and IL-6 levels in DCs indicates that the TLR4 
signal is activated and the cells are ready to initiate the immune response. Our results 
showed that DCs that were treated with CLI-095 and subjected to hypoxia and re-
oxygenation secreted less TNF-α and IL-6 than cells that were stimulated without 
treatment (Figure 5). This suggests that CLI-095 has suppressive effects on the 
production of pro-inflammatory mediators. Our data also showed that the inhibitory 
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effects of CLI-095 on the production of TNF-α and IL-6 were the same in both DCs and 
macrophages (Figures 5 and 6), which indicates that the difference in the type of innate 
immune cells does not affect the efficacy of the CLI-095.    
As mentioned earlier, TLR4 activation triggers several kinases, such as IRAK4, 
which results in translocation of NF-κB, the transcription of pro-inflammatory cytokines 
and chemokines, and DC maturation [60]. Furthermore, our results suggest that CLI-095 
targets an event that occurs before the transcription of pro-inflammatory cytokines. 
Therefore, we examined the effect of CLI-095 on the IRAK4 and NF-κB signaling 
pathways in response to hypoxia and re-oxygenation. The IRAK4 and NF-κB expression 
levels were greatly reduced in CLI-095-treated DCs compared to cells that were not 
treated (Figure 4), indicating that CLI-095 can block the activation of the TLR4 signal in 
DCs induced by hypoxia and re-oxygenation. 
Taken together, our study demonstrated the role of TLR4 in innate immunity 
activation in response to hypoxia and re-oxygenation. In addition, the results showed that 
untreated DCs were more matured than DCs pretreated with CLI-095: DC maturation and 
the secretion of cytokines and chemokines after exposure to inflammatory stimuli were 
decreased in pretreated DCs. Moreover, our results showed that CLI-095 inhibited the 
TLR4-signaling pathways, but not the TLR4 itself. Several studies have reported that 
CLI-095 could have a potential role in treating inflammation-related diseases. CLI-095 
protects against acute cerebral IRI and could be considered as a potential therapeutic 
strategy to constrain the inflammatory process in other types of IRI, such as renal IRI 
[107].  
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In conclusion, we have characterized a new molecule, CLI-095, which 
specifically and significantly downregulates TLR4. In addition, we have shown that DCs 
are activated in hypoxia and re-oxygenation models, and that CLI-095 has a significant 
impact in reducing DC activation. Therefore, TLR4 is an important innate immune 
receptor implicated in hypoxia and re-oxygenation. Since hypoxia and re-oxygenation 
represent an in vitro model of IRI, CLI-095 might be useful as a potential therapeutic 
target for reducing renal IRI. Most immune cells are overloaded with TLR4 considering a 
more robust role of neutrophil in IRI and DCs in organ rejection, manipulating their 
TLR4 pathway could be a logical target in both. 
38 
 
5 Future direction 
The future direction of this project involves determining CLI-095’s role in 
modulating DCs and their TLR4 expression in an animal model of kidney IRI. To obtain 
such a model, C57BL/6 mice will be subjected to left kidney pedicle clamping for 50 
min, and then the clamping will be released and the right kidney will be removed. 
Control groups will include untreated animals and animals subjected to laparotomy alone. 
The mice will be treated with CLI-095 for 1 hr or 18 hrs prior to clamping. The mice will 
be exsanguinated, and both kidneys will be collected 24 hrs after clamping and release. 
Kidney function (creatinine, proteinuria) will be assessed, and immunohistochemistry, 
H&E, TUNEL, and TLR4 staining will be performed.  
In addition, the effect of CLI-095 in pretreated allograft kidneys will be 
determined. Kidneys will be taken from donor BALB/c mice and stored for 24 hrs in a 
cold standard UW preservation solution (mimics DCD=donation after cardiac death), 
which will be supplemented with group 1 CLI-095 and group 2 standard UW 
preservation solution only. Renal transplant with the treated kidney will be performed on 
C57BL/6 mice, and then all animals will receive a sub-therapeutic regimen of tacrolimus. 
Graft function (creatinine, proteinuria) and survival will be assessed on days 0, 8, and 30. 
Assessment for rejection (H&E), DCs (CD11c, CD80, CD86, TLR4, and 9), T cell 
infiltration, cytokines, and adhesion molecules will be assessed using qRT-PCR, Western 
blot, or immunohistochemistry. The use of animal models is an important step in the 
translation of our in vitro study to a clinical setting, and will allow us to confirm our 
results. 
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Appendices 
A. Analysis of surface maturation marker expression in DC in 
response to LPS (TLR4-specific ligand) 
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Cells stimulated with LPS (50 ng/ml) for 12 hrs and compared to normal cells 
(cells without treatment). Flow cytometry analysis of MHCII, CD80, CD83, and CD86 
showed that LPS stimulation significantly increased the expression of these cytokines in 
LPS-stimulated DCs. Results are representative of five different experiments. Error bars 
represent SD, * p < 0.05, ** p < 0.002, *** p < 0.001, **** p < 0.0001. 
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B. Analysis of cell surface marker expression in DCs in 
response to LPS stimulation and CLI095 treatment 
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Cells stimulated with LPS (50 ng/ml) compared to cells that were treated with 
CLI095 (100 μg/ml) for 3 hrs before stimulation with LPS for 12 hrs (CLI095+LPS) and 
DCs treated with CLI095 and incubated for 3 hrs (CLI095). Flow cytometry analysis of 
MHCII, CD80, CD83, and CD86 showed that LPS stimulation significantly increased the 
expression of these cytokines compared to unstimulated cells. Cells treated with CLI095 
for 3 hrs before stimulation showed significant reductions in MHCII, CD80, and CD86 
compared to LPS-stimulated cells. Results are representative of five different 
experiments. Error bars represent SD, * p < 0.05, ** p < 0.002, *** p < 0.001, **** p < 
0.0001. 
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C. CLI-095’s protective effects on DC pro-inflammatory 
cytokines in response to LPS  
 
Cytokine production by DCs stimulated with no treatment (normal), CLI-095 
(100μg/ml), LPS (50 ng/ml), or both CLI-095+LPS. DCs were stimulated with LPS 
(50 ng/ml) for 12 hrs and their cytokine production was compared to that of untreated 
cells (normal), cells treated with CLI-095 (100μg/ml) for 3 hrs before stimulation with 
LPS for 12 h (CLI-095+LPS), and DCs treated with CLI-095 and incubated for 3 hrs 
(CLI095). The culture media were collected and IL6 (A) and TNF-α (B) were quantified 
by ELISA. Results are expressed as mean pg/ml ± SE from three independent 
experiments. Cells treated with CLI-095 showed reductions in pro-inflammatory cytokine 
levels (TNFα and IL6) compared to cells that were only subjected to LPS. * p < 0.05, ** 
p < 0.002, *** p < 0.001, **** p < 0.0001. 
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